Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

The Lancet Oncology

Volumn 10, Issue 10, 2009, Pages 967-974

  Je, Youjin ^a   Schutz, Fabio AB ^b   Choueiri, Toni K ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; PLACEBO; SORAFENIB; SUNITINIB;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; CARCINOID; CLINICAL TRIAL; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENITAL BLEEDING; GINGIVA BLEEDING; HEAD AND NECK CARCINOMA; HEMATOMA; HEMOPTYSIS; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTUM HEMORRHAGE; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; THYROID CANCER; TUMOR BLEEDING; UPPER GASTROINTESTINAL BLEEDING; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; INCIDENCE; INDOLES; PYRIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK ASSESSMENT;

EID: 70349393610     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70222-0     Document Type: Article

References (48)

1. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175 (1972) 409-416
2. Kamba T., and McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96 (2007) 1788-1795
3. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
4. Llovet J.M., Ricci S., Mazzaferro V., et al., for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
5. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
6. National Cancer Institute. Active trials database. http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid=6605091 (accessed June 2, 2009).
7. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
8. Elice F., Jacoub J., Rickles F.R., Falanga A., and Rodeghiero F. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 83 (2008) 862-870
9. Hall P.S., Kancherla K., Sastry P.S., and Brown J.E. Severe epistaxis with tyrosine kinase inhibitors. Clin Oncol (R Coll Radiol) 20 (2008) 318-319
10. Pouessel D., and Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53 (2008) 376-381
11. Sher AF, Chu D, Wu S. Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: a meta-analysis. 2009 ASCO annual meeting; Orlando, FL, USA; May 29-June 2, 2009. Abstract 9584.
12. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
13. Bayer. NEXAVAR: highlights of prescribing information. http://www.univgraph.com/bayer/inserts/nexavar.pdf (accessed June 2, 2009).
14. Pfizer. SUTENT: highlights of prescribing information. https://www.pfizeroncology.com/sites/pop/PDFs/uspi_sutent.pdf (accessed June 2, 2009).
15. Hopewell S., Clarke M., Moher D., et al., for the CONSORT group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet 371 (2008) 281-283
16. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
17. Eisen T., Beck J., Procopio G., et al. Large open-label, non-comparative phase III study of sorafenib in European pts with advanced RCC (EU-ARCCS): subgroup analysis of pts with and without baseline clinical cardiovascular diseases (CCD). Ann Oncol 19 suppl 8 (2008) viii194 (abstr 602P).
18. Hobday TJ, Rubin J, Holen K et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. 2007 ASCO annual meeting; Chicago, IL, USA; June 1-5, 2007. Abstract 4504.
19. Kulke M.H., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26 (2008) 3403-3410
20. Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. 2008 ASCO annual meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 8014.
21. Wiebe L, Kasza KE, Maki RG, et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. 2008 ASCO annual meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 10502.
22. Choong NW, Cohen EE, Kozloff MF, et al. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). 2008 ASCO annual meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 6064.
23. George S, Casali PG, Blay J, et al. Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. 2006 ASCO annual meeting; Atlanta, GA, USA; June 2-6, 2006. Abstract 9532.
24. Gollob J.A., Rathmell W.K., Richmond T.M., et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25 (2007) 3288-3295
25. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26 (2008) 4714-4719
26. Yau T., Chan P., Ng K.K., et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115 (2009) 428-436
27. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
28. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
29. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994) 1088-1101
30. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
31. Escudier B., Eisen T., Stadler W.M., et al., for the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
32. Porta C, Szczylik C, Bracarda S, et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). 2008 ASCO annual meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 5114.
33. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
34. Brahmer JR, Govindan R, Novello S, et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. 2007 ASCO annual meeting; Chicago, IL, USA; June 1-5, 2007. Abstract 7542.
35. Gatzemeier U, Blumenschein G, Fosella F. et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. 2006 ASCO annual meeting; Atlanta, GA, USA; June 2-6, 2006. Abstract 7002.
36. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26 (2008) 1810-1816
37. Bellmunt J, Maroto P, Mellado B, et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. 2008 ASCO Genitourinary Cancer Symposium; San Francisco, CA, USA; Feb 14-16, 2008. Abstract 291.
38. O'Reilly EM, Niedzwiecki D, Hollis DR, et al. A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. 2008 ASCO annual meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 4515.
39. Ravaud A, de la Fouchardière C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. 2008 ASCO annual meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 6058.
40. Rini B.I., Michaelson M.D., Rosenberg J.E., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26 (2008) 3743-3748
41. Socinski M.A., Novello S., Brahmer J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26 (2008) 650-656
42. Choueiri T.K., Vaziri S.A., Jaeger E., et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180 (2008) 860-866
43. Patel P.H., Chaganti R.S., and Motzer R.J. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94 (2006) 614-619
44. Chu D., Lacouture M.E., Weiner E., and Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7 (2009) 11-19
45. Kim CY, Chu D, Baer L, Wu S. High-grade proteinuria associated with bevacizumab in patients with renal cell cancer and non-renal cell cancer. 2009 ASCO annual meeting; Orlando, FL, USA; May 29-June 2, 2009. Abstract e16089.
46. Kilickap S., Abali H., and Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 21 (2003) 3542-3543
47. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
48. Carden C.P., Larkin J.M., and Rosenthal M.A. What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol 10 (2008) 624-630